710 related articles for article (PubMed ID: 15698861)
1. Selectivity of febuxostat, a novel non-purine inhibitor of xanthine oxidase/xanthine dehydrogenase.
Takano Y; Hase-Aoki K; Horiuchi H; Zhao L; Kasahara Y; Kondo S; Becker MA
Life Sci; 2005 Mar; 76(16):1835-47. PubMed ID: 15698861
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetics and pharmacodynamics of febuxostat (TMX-67), a non-purine selective inhibitor of xanthine oxidase/xanthine dehydrogenase (NPSIXO) in patients with gout and/or hyperuricemia.
Komoriya K; Hoshide S; Takeda K; Kobayashi H; Kubo J; Tsuchimoto M; Nakachi T; Yamanaka H; Kamatani N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1119-22. PubMed ID: 15571213
[TBL] [Abstract][Full Text] [Related]
3. Febuxostat: a selective xanthine-oxidase/xanthine-dehydrogenase inhibitor for the management of hyperuricemia in adults with gout.
Ernst ME; Fravel MA
Clin Ther; 2009 Nov; 31(11):2503-18. PubMed ID: 20109996
[TBL] [Abstract][Full Text] [Related]
4. Febuxostat: a selective xanthine oxidase inhibitor for the treatment of hyperuricemia and gout.
Bruce SP
Ann Pharmacother; 2006 Dec; 40(12):2187-94. PubMed ID: 17132810
[TBL] [Abstract][Full Text] [Related]
5. An allopurinol-controlled, randomized, double-dummy, double-blind, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 3 clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S13-8. PubMed ID: 21654265
[TBL] [Abstract][Full Text] [Related]
6. Febuxostat (Teijin/Ipsen/TAP).
Tomlinson B
Curr Opin Investig Drugs; 2005 Nov; 6(11):1168-78. PubMed ID: 16312139
[TBL] [Abstract][Full Text] [Related]
7. Febuxostat (TMX-67), a novel, non-purine, selective inhibitor of xanthine oxidase, is safe and decreases serum urate in healthy volunteers.
Becker MA; Kisicki J; Khosravan R; Wu J; Mulford D; Hunt B; MacDonald P; Joseph-Ridge N
Nucleosides Nucleotides Nucleic Acids; 2004 Oct; 23(8-9):1111-6. PubMed ID: 15571211
[TBL] [Abstract][Full Text] [Related]
8. The xanthine oxidase inhibitor febuxostat suppresses development of nonalcoholic steatohepatitis in a rodent model.
Nakatsu Y; Seno Y; Kushiyama A; Sakoda H; Fujishiro M; Katasako A; Mori K; Matsunaga Y; Fukushima T; Kanaoka R; Yamamotoya T; Kamata H; Asano T
Am J Physiol Gastrointest Liver Physiol; 2015 Jul; 309(1):G42-51. PubMed ID: 25999428
[TBL] [Abstract][Full Text] [Related]
9. Effect of TEI-6720, a xanthine oxidase inhibitor, on the nucleoside transport in the lung cancer cell line A549.
Yamamoto T; Moriwaki Y; Fujimura Y; Takahashi S; Tsutsumi Z; Tsutsui T; Higashino K; Hada T
Pharmacology; 2000 Jan; 60(1):34-40. PubMed ID: 10629441
[TBL] [Abstract][Full Text] [Related]
10. Hypouricemic effect of the novel xanthine oxidase inhibitor, TEI-6720, in rodents.
Osada Y; Tsuchimoto M; Fukushima H; Takahashi K; Kondo S; Hasegawa M; Komoriya K
Eur J Pharmacol; 1993 Sep; 241(2-3):183-8. PubMed ID: 8243554
[TBL] [Abstract][Full Text] [Related]
11. Chronic xanthine oxidase inhibition following myocardial infarction in rabbits: effects of early versus delayed treatment.
Zhao L; Roche BM; Wessale JL; Kijtawornrat A; Lolly JL; Shemanski D; Hamlin RL
Life Sci; 2008 Feb; 82(9-10):495-502. PubMed ID: 18215719
[TBL] [Abstract][Full Text] [Related]
12. Febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase: a twenty-eight-day, multicenter, phase II, randomized, double-blind, placebo-controlled, dose-response clinical trial examining safety and efficacy in patients with gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Palo WA; Eustace D; Vernillet L; Joseph-Ridge N
Arthritis Rheum; 2005 Mar; 52(3):916-23. PubMed ID: 15751090
[TBL] [Abstract][Full Text] [Related]
13. Febuxostat compared with allopurinol in patients with hyperuricemia and gout.
Becker MA; Schumacher HR; Wortmann RL; MacDonald PA; Eustace D; Palo WA; Streit J; Joseph-Ridge N
N Engl J Med; 2005 Dec; 353(23):2450-61. PubMed ID: 16339094
[TBL] [Abstract][Full Text] [Related]
14. A comparative study on the hypouricemic activity and potency in renal xanthine calculus formation of two xanthine oxidase/xanthine dehydrogenase inhibitors: TEI-6720 and allopurinol in rats.
Horiuchi H; Ota M; Kobayashi M; Kaneko H; Kasahara Y; Nishimura S; Kondo S; Komoriya K
Res Commun Mol Pathol Pharmacol; 1999; 104(3):307-19. PubMed ID: 10741381
[TBL] [Abstract][Full Text] [Related]
15. The screening and characterization of 6-aminopurine-based xanthine oxidase inhibitors.
Hsieh JF; Wu SH; Yang YL; Choong KF; Chen ST
Bioorg Med Chem; 2007 May; 15(10):3450-6. PubMed ID: 17379526
[TBL] [Abstract][Full Text] [Related]
16. The effect of age and gender on pharmacokinetics, pharmacodynamics, and safety of febuxostat, a novel nonpurine selective inhibitor of xanthine oxidase.
Khosravan R; Kukulka MJ; Wu JT; Joseph-Ridge N; Vernillet L
J Clin Pharmacol; 2008 Sep; 48(9):1014-24. PubMed ID: 18635756
[TBL] [Abstract][Full Text] [Related]
17. An allopurinol-controlled, multicenter, randomized, open-label, parallel between-group, comparative study of febuxostat (TMX-67), a non-purine-selective inhibitor of xanthine oxidase, in patients with hyperuricemia including those with gout in Japan: phase 2 exploratory clinical study.
Kamatani N; Fujimori S; Hada T; Hosoya T; Kohri K; Nakamura T; Ueda T; Yamamoto T; Yamanaka H; Matsuzawa Y
J Clin Rheumatol; 2011 Jun; 17(4 Suppl 2):S44-9. PubMed ID: 21654269
[TBL] [Abstract][Full Text] [Related]
18. Xanthine oxidase inhibitors beyond allopurinol and febuxostat; an overview and selection of potential leads based on in silico calculated physico-chemical properties, predicted pharmacokinetics and toxicity.
Šmelcerović A; Tomović K; Šmelcerović Ž; Petronijević Ž; Kocić G; Tomašič T; Jakopin Ž; Anderluh M
Eur J Med Chem; 2017 Jul; 135():491-516. PubMed ID: 28478180
[TBL] [Abstract][Full Text] [Related]
19. Febuxostat for prevention of gout attacks.
Pohar S; Murphy G
Issues Emerg Health Technol; 2006 Aug; (87):1-4. PubMed ID: 16958189
[TBL] [Abstract][Full Text] [Related]
20. Febuxostat: a non-purine, selective inhibitor of xanthine oxidase for the management of hyperuricaemia in patients with gout.
Schumacher HR
Expert Opin Investig Drugs; 2005 Jul; 14(7):893-903. PubMed ID: 16022578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]